85.04
price down icon0.40%   -0.34
after-market After Hours: 85.27 0.23 +0.27%
loading
Astrazeneca PLC stock is traded at $85.04, with a volume of 9.09M. It is down -0.40% in the last 24 hours and up +4.70% over the past month. AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$85.38
Open:
$85.9
24h Volume:
9.09M
Relative Volume:
1.94
Market Cap:
$263.74B
Revenue:
$56.53B
Net Income/Loss:
$8.32B
P/E Ratio:
31.94
EPS:
2.6622
Net Cash Flow:
$8.49B
1W Performance:
+1.66%
1M Performance:
+4.70%
6M Performance:
+27.38%
1Y Performance:
+9.72%
1-Day Range:
Value
$84.99
$86.38
1-Week Range:
Value
$83.84
$86.57
52-Week Range:
Value
$61.24
$86.57

Astrazeneca PLC Stock (AZN) Company Profile

Name
Name
Astrazeneca PLC
Name
Phone
44 20 3749 5000
Name
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Name
Employee
61,100
Name
Twitter
@AstraZeneca
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
AZN's Discussions on Twitter

Compare AZN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Major icon
AZN
Astrazeneca PLC
85.04 264.72B 56.53B 8.32B 8.49B 2.6622

Astrazeneca PLC Stock (AZN) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-15-25 Initiated Exane BNP Paribas Outperform
Feb-13-25 Upgrade UBS Neutral → Buy
Feb-12-25 Initiated Morgan Stanley Overweight
Nov-20-24 Upgrade UBS Sell → Neutral
Nov-06-24 Upgrade Deutsche Bank Sell → Hold
Sep-13-24 Downgrade Deutsche Bank Hold → Sell
May-30-24 Initiated Goldman Buy
Apr-16-24 Upgrade Deutsche Bank Sell → Hold
Feb-08-24 Downgrade Deutsche Bank Hold → Sell
Jan-23-24 Initiated Morgan Stanley Overweight
Jan-16-24 Resumed UBS Sell
Jan-03-24 Downgrade Jefferies Buy → Hold
Dec-18-23 Initiated HSBC Securities Buy
Sep-25-23 Upgrade Jefferies Hold → Buy
Jul-14-23 Initiated HSBC Securities Buy
Jul-12-23 Upgrade UBS Neutral → Buy
Jul-05-23 Downgrade Deutsche Bank Buy → Hold
Apr-11-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-05-23 Initiated BMO Capital Markets Outperform
Sep-15-22 Downgrade Credit Suisse Outperform → Neutral
Sep-07-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Aug-29-22 Upgrade Argus Hold → Buy
Jun-14-22 Downgrade UBS Buy → Neutral
Feb-11-22 Upgrade DZ Bank Sell → Hold
Dec-07-21 Downgrade Jefferies Buy → Hold
Aug-12-21 Resumed JP Morgan Overweight
Apr-12-21 Downgrade Argus Buy → Hold
Mar-16-21 Upgrade Jefferies Hold → Buy
Feb-25-21 Upgrade UBS Neutral → Buy
Jan-15-21 Initiated Deutsche Bank Buy
Dec-07-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-30-20 Upgrade UBS Sell → Neutral
Nov-11-20 Upgrade HSBC Securities Reduce → Hold
Sep-29-20 Initiated Berenberg Buy
Nov-22-19 Initiated SVB Leerink Outperform
Oct-25-19 Upgrade Liberum Hold → Buy
Apr-02-19 Downgrade UBS Neutral → Sell
Feb-05-19 Initiated Exane BNP Paribas Outperform
Jan-25-19 Upgrade Shore Capital Hold → Buy
Dec-11-18 Resumed Jefferies Hold
Oct-09-18 Initiated Guggenheim Buy
Aug-16-18 Downgrade Jefferies Buy → Hold
Mar-19-18 Upgrade Jefferies Hold → Buy
Feb-06-18 Reiterated Leerink Partners Mkt Perform
Feb-05-18 Reiterated Bernstein Outperform
Jan-18-18 Reiterated Leerink Partners Mkt Perform
Dec-29-17 Upgrade JP Morgan Neutral → Overweight
Oct-16-17 Upgrade Credit Suisse Neutral → Outperform
Sep-25-17 Upgrade Exane BNP Paribas Neutral → Outperform
Sep-22-17 Upgrade Bernstein Mkt Perform → Outperform
View All

Astrazeneca PLC Stock (AZN) Latest News

pulisher
01:34 AM

AstraZeneca boosts investment in Virginia plant (AZN:NASDAQ) - Seeking Alpha

01:34 AM
pulisher
01:12 AM

AstraZeneca to invest $4.5 billion in Virginia manufacturing facility By Investing.com - Investing.com South Africa

01:12 AM
pulisher
01:07 AM

AstraZeneca to invest $4.5B in Virginia facility - breakingthenews.net

01:07 AM
pulisher
01:03 AM

AstraZeneca ups investment at new Virginia facility to USD4.5 billion - MarketScreener

01:03 AM
pulisher
12:56 PM

AstraZeneca (AZN) Invests $4.5B in New Virginia Facility to Boos - GuruFocus

12:56 PM
pulisher
12:53 PM

AstraZeneca to increase investment & scope of Virginia manufacturing facility to $4.5 bln - MarketScreener

12:53 PM
pulisher
12:31 PM

AstraZeneca breaks ground at $4.5 billion Virginia plant as drugmakers court Trump - MarketScreener

12:31 PM
pulisher
12:30 PM

3,600 Jobs: AstraZeneca Expands Virginia Investment to $4.5B, Adds ADC Cancer Manufacturing - Stock Titan

12:30 PM
pulisher
10:21 AM

Turbine Launches Collaboration with Astrazeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery - MarketScreener

10:21 AM
pulisher
07:56 AM

What machine learning models say about AstraZeneca PLC Depositary ReceiptWeekly Market Outlook & High Accuracy Buy Signal Tips - newser.com

07:56 AM
pulisher
06:32 AM

AstraZeneca (AZN) Unaffected by Potential Tariffs on Generic Dru - GuruFocus

06:32 AM
pulisher
06:27 AM

Volume spikes in AstraZeneca PLC Depositary Receipt stock – what they meanWeekly Stock Recap & Real-Time Market Sentiment Alerts - newser.com

06:27 AM
pulisher
06:24 AM

Algen inks $555m AstraZeneca partnership for AI-powered drug discovery - BioXconomy

06:24 AM
pulisher
06:01 AM

Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery - MarketScreener

06:01 AM
pulisher
05:50 AM

Advanced analytics toolkit walkthrough for AstraZeneca PLC Depositary Receipt2025 Price Action Summary & AI Driven Price Forecasts - newser.com

05:50 AM
pulisher
05:14 AM

Will AstraZeneca PLC Depositary Receipt bounce back from current supportEarnings Risk Report & High Yield Stock Recommendations - newser.com

05:14 AM
pulisher
04:52 AM

AstraZeneca PLC $AZN Shares Sold by Prime Capital Investment Advisors LLC - MarketBeat

04:52 AM
pulisher
04:24 AM

AstraZeneca PLC (AZN)’s Datroway Wins FDA Nod for Lung Cancer Breakthrough - MSN

04:24 AM
pulisher
04:23 AM

AstraZeneca PLC Depositary Receipt recovery potential after sell off2025 Price Action Summary & Verified Momentum Stock Ideas - newser.com

04:23 AM
pulisher
03:42 AM

AstraZeneca PLC Depositary Receipt stock momentum explained2025 Performance Recap & Step-by-Step Swing Trade Plans - newser.com

03:42 AM
pulisher
03:38 AM

Stock of the Week: Is AstraZeneca a Buy After Share Price Jump? - Morningstar Canada

03:38 AM
pulisher
01:42 AM

Barclays Keeps AstraZeneca at Overweight, Expects 'Resilient' Q3 Results - MarketScreener

01:42 AM
pulisher
Oct 08, 2025

AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study - Yahoo Finance

Oct 08, 2025
pulisher
Oct 08, 2025

What AstraZeneca Can Teach Us About Scaling Innovation Through Ecosystem Collaboration - MarketScreener

Oct 08, 2025
pulisher
Oct 08, 2025

AstraZeneca Shares Surge 14% as Investment Pause Spurs Fresh Valuation Debate - Yahoo

Oct 08, 2025
pulisher
Oct 07, 2025

Thermo Fisher's New R&D Alliance With AstraZeneca May Lift Its Stock - sharewise.com

Oct 07, 2025
pulisher
Oct 07, 2025

AstraZeneca's Baxdrostat Shows Meaningful Blood Pressure Control In Patients With Resistant Hypertension - Benzinga

Oct 07, 2025
pulisher
Oct 07, 2025

Another Baxdrostat Success Takes Pressure Off AstraZeneca - insights.citeline.com

Oct 07, 2025
pulisher
Oct 07, 2025

AstraZeneca PLC Announces Baxdrostat Met Primary Endpoints in Bax24 Phase Iii Trial in Patients with Resistant Hypertension - MarketScreener

Oct 07, 2025
pulisher
Oct 07, 2025

AstraZeneca (LSE:AZN): Exploring Valuation as Shares Move Steadily Higher - Yahoo Finance

Oct 07, 2025
pulisher
Oct 07, 2025

AstraZeneca PLC $AZN Stock Holdings Lowered by Meitav Investment House Ltd. - MarketBeat

Oct 07, 2025
pulisher
Oct 07, 2025

AstraZeneca (AZN) Reports Success in Phase 3 Hypertension Trial - GuruFocus

Oct 07, 2025
pulisher
Oct 07, 2025

AstraZeneca Reports Positive Bax24 Trial Results for Hypertension - AskTraders.com

Oct 07, 2025
pulisher
Oct 07, 2025

AstraZeneca Says Phase 3 Trial of Baxdrostat Meets Endpoint in Resistant Hypertension - MarketScreener

Oct 07, 2025
pulisher
Oct 07, 2025

AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Oct 07, 2025
pulisher
Oct 07, 2025

AstraZeneca reports Phase III trial success for baxdrostat in hypertension - Investing.com

Oct 07, 2025
pulisher
Oct 07, 2025

AstraZeneca PLC Announces Baxdrostat Demonstrates A Statistically Significant and Highly clinically meaningful Reduction in 24-Hour Systolic Blood Pressure Compared with Placebo - MarketScreener

Oct 07, 2025
pulisher
Oct 07, 2025

AstraZeneca drug baxdrostat cuts blood pressure in key late-stage trial - MarketScreener

Oct 07, 2025
pulisher
Oct 07, 2025

AstraZeneca and Daiichi’s Datroway trumps chemo in first-line breast cancer - clinicaltrialsarena.com

Oct 07, 2025
pulisher
Oct 07, 2025

D.B. Root & Company LLC Cuts Stake in AstraZeneca PLC $AZN - MarketBeat

Oct 07, 2025
pulisher
Oct 07, 2025

BreakingviewsAstraZeneca’s New York shift augurs London exodus - Reuters

Oct 07, 2025
pulisher
Oct 07, 2025

AstraZeneca blood pressure drug succeeds in late-stage trial - Financial Times

Oct 07, 2025
pulisher
Oct 07, 2025

AstraZeneka presents results for patients with resistant hypertension - MarketScreener

Oct 07, 2025
pulisher
Oct 07, 2025

AstraZeneca’s experimental hypertension drug shows promising results - Investing.com

Oct 07, 2025
pulisher
Oct 07, 2025

AstraZeneca’s baxdrostat hits key goal in major blood pressure trial - Proactive financial news

Oct 07, 2025
pulisher
Oct 07, 2025

AstraZeneca says baxdrostat met primary endpoint in BAX24 Ph3 trial - MarketScreener

Oct 07, 2025
pulisher
Oct 07, 2025

AstraZeneca : Baxdrostat met primary endpoint in Bax24 Ph3 trial - MarketScreener

Oct 07, 2025
pulisher
Oct 07, 2025

REGAstraZeneca PLCBaxdrostat met primary endpoint in Bax24 Ph3 trial - TradingView

Oct 07, 2025
pulisher
Oct 06, 2025

AstraZeneca Taps Gene Editing And AI Platform For Drug Discovery For Immunology Diseases - Benzinga

Oct 06, 2025
pulisher
Oct 06, 2025

AstraZeneca (AZN) Achieves Key Milestones in Breast Cancer Treat - GuruFocus

Oct 06, 2025
pulisher
Oct 06, 2025

AstraZeneca, Daiichi Sankyo succeed in late-stage breast cancer study - Seeking Alpha

Oct 06, 2025

Astrazeneca PLC Stock (AZN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
Cap:     |  Volume (24h):